作者： nicole

HONG KONG, Apr 9, 2025 - (ACN Newswire via SeaPRwire.com) - - The 2nd Smart Lighting Expo and 16th Hong Kong International Lighting Fair (Spring Edition) concluded successfully today- The twin fairs attracted some 15,000 buyers from 108 countries and regions, with increased numbers from various markets in Asia, Europe and Latin America- An on-site survey showed that more than half of respondents still anticipate sales rising in the next one to two years- InnoEX and Hong Kong Electronics Fair (Spring Edition) will open on Sunday, 13 April at the Hong Kong Convention and Exhibition CentreHONG KONG, Apr 9, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC), the 2nd Smart Lighting Expo and 16th Hong Kong International Lighting Fair (Spring Edition) successfully concluded today. The twin fairs welcomed some 15,000 buyers from 108 countries and regions, with notable growth in buyers from Asia including Indonesia, Korea, Taiwan and Thailand, European countries, such as the Czech Republic, the Netherlands and Poland, as well as from Latin America, including Argentina and Colombia. This participation highlights the prominent role both fairs have as global trading platforms for lighting products.Sophia Chong, Deputy Executive Director of the HKTDC, said: “As the first wave of HKTDC’s four spring tech events in April, the twin lighting fairs showcased the most advanced lighting products and solutions. Hosting various industry seminars and networking events, the fairs served as an ideal platform for professionals to expand their connections and discuss trending market topics, driving industry development in greenovation, healthy lighting, and smart technology. This Sunday, InnoEX and Hong Kong Electronics Fair (Spring Edition) will open for four days, reinforcing Hong Kong's position as a leading, international innovation and technology hub.”Home automation and smart lighting control systems reveal competitive edgeThe HKTDC conducted a survey to gain a deeper understanding of the trends in the lighting industry and surveyed 446 exhibitors and buyers on-site. The results indicate that both buyers and exhibitors are still positive about the economic outlook.Highlighted market outlook and product trends:- Within the next 6 to 12 months, 38.3% of respondents anticipate an increase in overall sales, while 52.2% expect sales to remain stable. Over the next 1 to 2 years, 51.8% expect overall sales to increase, with 39.7% anticipate sales to remain stable.- Respondents consider Taiwan (77.1%), Mainland China (76.2%), Hong Kong (70.6%), Japan (65.8%), and ASEAN countries (63.3%) to be promising or very promising target sales markets for lighting products over the next two years in terms of growth.- In terms of market potential, the most sought-after markets for respondents are Europe (24.2%), Australia and Pacific Islands (17.3%), North America (17.3%), ASEAN countries (13.3%), and Latin America (13.3%).- Respondents identify LED lighting (36.8%), residential lighting (25.1%), and commercial lighting (24.4%) as having the greatest growth potential.- Respondents believe home automation and smart lighting control systems (48.9%), energy-efficient lighting control solutions (39%), and outdoor smart security lighting systems (25.8%) have the most potential for smart lighting products in the next two years.- The survey revealed that consumers would be willing to pay an average 28% more for smart-lighting products.Trade discussions gain positive momentumSmart lighting products and solutions integrating artificial intelligence (AI) and Internet of Things (IoT) continued to be a focal point at the fair. The British brand Limi, participated for the first time in the Spring Lighting Fair and showcased its self-developed AI smart lighting control system. The company’s founder and CEO, Umer Asif stated, “The Spring Lighting Fair is the first international lighting fair we have joined. The fair allows us to introduce our new lighting concept to global buyers and enhance our exposure. We have connected with more than 200 buyers from Hong Kong, Europe, Saudi Arabia and the US. We have had preliminary negotiations with more than 50 potential business partners. We expect the fair to bring in US$40 to US$50 million in sales for the company. Due to the favourable results, we have already reserved a bigger booth at the Autumn Lighting Fair.”The Hall of Aurora at the Spring Lighting Fair featured some 180 elite lighting brands including Hong Kong brand Siki - a renowned lighting brand for Mainland China's catering industry specialising in functional LED lighting products. Ye Chang, General Manager of Liang Owltech Company Limited, said: "To expand into overseas markets and establish Siki as a global brand, we participate annually in the Hong Kong International Lighting Fair. At this year's Spring Lighting Fair, we have met various new buyers from Europe, the Middle East, and Southeast Asia, with some 30 potential clients will place orders, we anticipate order sales to reach US$500,000 to US$1 million.”Smart city initiatives have consistently driven the rapid growth of the smart lighting market. Buyers from Brazil's Azizi are dedicated to sourcing quality lighting products for Brazilian companies and government projects. The company’s CEO and founder, Fábio Oliveira said, “Since 2012, I have actively attended the lighting fairs. At this year's Smart Lighting Expo, I have already identified three potential suppliers for smart controllers needed for a street light project, with orders valued at approximately US$1.2 million. My sourcing journey will also continue through the Click2Match platform, ensuring we stay connected with more suppliers after the fairs."Hungary's Seemis Kft is keen to source lighting products from manufacturers in Mainland China for better quality and prices. The company’s Chief Executive Officer, Magyar Krisztina said, “After attending the meetings arranged via the Click2Match platform, we have found three potential suppliers of track lights, linear lights, tri-proof lights and floodlights from Mainland China. We plan to buy US$150,000 to US$200,000 worth of lighting products at the Spring Lighting Fair.”Under the hybrid EXHIBITION+ model, the twin lighting fairs combined in-person sourcing with online meetings via the HKTDC’s Click2Match smart business-matching platform and hktdc.com sourcing platform. Click2Match will be available until 16 April to facilitate discussions between exhibitors and buyers around the world.April brings a calendar packed with innovation and trade eventsDriven by the Government of the Hong Kong Special Administrative Region’s Innovation, Technology and Industry Bureau and the HKTDC, Business of Innovation & Technology Week (BIT Week) in April 2025 brings together a series of tech-related exhibitions, conferences, seminars, roundtables and networking events in Hong Kong, setting the perfect scene for industry exchanges and cross-disciplinary collaborations. A series of exciting must-attend technology events during the week, include the just-ended Smart Lighting Expo and Hong Kong Web3 Festival, as well as upcoming events starting on Sunday, such as InnoEX, Hong Kong Electronics Fair (Spring Edition), and the Hong Kong World Youth Science Conference.Apart from BIT Week, the HKTDC will also host a series of lifestyle exhibitions later this month, including the Hong Kong Gifts & Premium Fair, Home InStyle, Fashion InStyle, Hong Kong International Printing & Packaging Fair, DeLuxe PrintPack Hong Kong, and Hong Kong International Licensing Show and Asian Licensing Conference, to promote Hong Kong's economic and trade development.Photo download: https://bit.ly/3GcOJtQThe 2nd Smart Lighting Expo and the 16th Hong Kong International Lighting Fair (Spring Edition) concluded successfully today, attracting some 15,000 buyers from 108 countries and regionsThe Greenovation zone debuted at the Spring Lighting Fair, showcasing innovative green lighting products and technologyThe Hall of Aurora at the Spring Lighting Fair featured innovative lighting products and technology from some 180 renowned brandsThe twin lighting fairs have attracted many exhibitors from major international lighting brandsThe Smart Lighting Fair featured group pavilions from Guangdong-Hong Kong-Macao Greater Bay Area, including two new pavilions from Shenzhen and a returning pavilion from ZhongshanThe Asian Lighting Forum took place on 6 April, facilitating the lighting industry to adapt to the latest market standards and illustrate the Environmental, Social, and Governance (ESG) development through case studiesIn the Smart Lighting Solution Forum on 7 April, industry experts presented technological advancements in human-centric lighting and comprehensive intelligent customised lighting application across different scenariosFair websitesSmart Lighting Expo: smartlightingexpo.hktdc.comHong Kong International Lighting Fair (Spring Edition): hklightingfairse.hktdc.comHKTDC Media Centre: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact HKTDC’s Communication & Public Affairs Department:Stanley SoTel: (852) 2584 4049Email: stanley.hp.so@hktdc.orgSerena CheungTel: (852) 2584 4272Email: serena.hm.cheung@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lawuw@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2025 ACN Newswire via SeaPRwire.com.

ATLANTA, GA, Apr 8, 2025 - (ACN Newswire via SeaPRwire.com) - Today marks a pivotal moment in the evolution of global infrastructure as Trading Nations Global officially releases its highly anticipated white paper: Empowering a Quantum-Resilient Future Through Collaboration. This visionary document lays the foundation for a digitally sovereign, quantum-ready world—one powered by decentralized cooperation, green technology, and AI-enabled infrastructure.In an age defined by uncertainty and fragmentation, Trading Nations Global is catalyzing a new era of digital diplomacy and sustainable innovation. Through a robust network of ambassadors spanning 16 global regions, the organization is coordinating the rollout of Regional Centers of Excellence (RCoEs)—localized, sovereign cloud hubs designed to secure data, enable AI, and operate autonomously through renewable energy.“We are not just imagining the future—we are actively building it,” said Earl Q. Davis, founder of Trading Nations Global.“This white paper is a call to unite governments, enterprises, and innovators around a shared infrastructure built for resilience, sovereignty, and sustainability.” said Michael E. Kempton, CEO, Trading Nations Global.Key Insights from the White Paper:Quantum-Resilient Infrastructure: RCoEs are fortified with post-quantum cryptography and tamper-proof digital lineage tracking to future-proof global data flows.Sovereign Cloud Ecosystem: Powered by the Vogon Cloud and the Distributed Quantum Ledger Database (DQLDB), this infrastructure allows for secure, low-latency, and borderless collaboration.Sustainability by Design: Each center is energy-autonomous, running on solar, wind, and hydrogen captured from ambient air—marking a shift toward truly off-grid operations.Partnership-Driven Deployment: Co-selling with Managed Service Providers (MSPs) ensures scalable, regionally tailored implementation with shared revenue models.Community-Led Governance: Infrastructure decisions are made locally, preserving cultural integrity, compliance, and trustImpactful Goals:In the next 12 months: Deploy RCoEs in all 16 regions and onboard over 500 organizations to the Vogon Cloud.By year two: Launch federated AI systems and establish Quantum Digital Asset governance.In the long term: Build a global mesh of quantum-sovereign nodes that power a post-silicon digital economy.This white paper presents not only a roadmap but a rallying point for global actors ready to transcend outdated paradigms. The Trading Nations framework balances high-tech resilience with ethical and equitable design principles—offering a scalable alternative to centralized digital monopoliesJoin the MovementTrading Nations Global is actively welcoming new coalition members—governments, technologists, businesses, and citizens—ready to co-create a secure and sustainable digital future.Read the full white paper and become part of the future today: www.tradingnations.cloud/docs/trading-nations-global-white-paper.pdfAbout Trading Nations GlobalTrading Nations Global is a pioneering global association committed to deploying quantum-resilient, community-led infrastructure that powers secure, interoperable, and sustainable digital economies. With a global footprint and an unwavering commitment to digital sovereignty, Trading Nations Global is building the backbone of tomorrow’s trade and governance. For more information, visit www.tradingnations.cloud/.Media Contact:AmplifiX / PlatodataBryan FeinbergZephyr@platodata.io  Copyright 2025 ACN Newswire via SeaPRwire.com.

KUALA LUMPUR, Apr 9, 2025 - (ACN Newswire via SeaPRwire.com) - The 3rd ASEAN Procurement Innovation Summit & Awards (APIS) 2025 is set to redefine the future of procurement by bringing together industry leaders, policymakers, and innovators to tackle the most pressing challenges and opportunities shaping the procurement landscape. Taking place on June 17-18, 2025, in Kuala Lumpur, Malaysia, this premier event will explore how procurement can drive innovation, sustainability, and digital transformation in an era of global disruptions and economic uncertainty.Procurement today is not just about cost control—it’s about strategic value creation, resilience, and technological innovation. As ASEAN economies push toward greater transparency, accountability, and efficiency, APIS 2025 will address how procurement can lead the way in reshaping supply chains, achieving ESG goals, and leveraging digital tools to enhance decision-making.Key Themes Include:Digital Procurement & AI: The role of AI, blockchain, and automation in transforming procurement processes.Supply Chain Resilience: Strategies for mitigating risks amid geopolitical and economic uncertainty.Sustainable & ESG-Driven Procurement: How to integrate ESG without compromising profitability.Future of Procurement Talent: Developing leadership and digital skills for the next-generation workforce.Procurement Intelligence & Value Creation: Leveraging data-driven insights for smarter procurement decisions.Technology & Governance: Ensuring accountability while adopting cutting-edge procurement technologies.Why Attend?APIS 2025 is more than just a conference—it’s a hub for procurement leaders to connect, collaborate, and shape the future. Attendees will benefit from:Exclusive Networking: Meet 50+ top procurement professionals, innovators, and decision-makers.Actionable Strategies: Gain insights into procurement best practices that can be implemented immediately.Thought Leadership: Learn from an esteemed lineup of keynote speakers driving procurement transformation.Future-Focused Discussions: Discover the latest trends, technologies, and strategies shaping procurement.Keynote SpeakersAPIS 2025 will feature an exceptional lineup of speakers, including:Dr. Christina Ooi – Former Chief Procurement Officer, APAC, Procurement ExpertLuke Kenny – CEO, Local Government ProcurementJonathan Cheung – General Manager APAC, The Chartered Institute of Procurement & Supply (CIPS)Gordon Donovan – Vice President Research, Procurement & External Workforce, SAPMathew Baldwin – Partner, Digital Economy, AshurstJuan Ignacio D’Altri – Advisor, Saudi AramcoSessions & DiscussionsAPIS 2025 will offer a diverse range of expert-led sessions, covering topics such as AI-powered procurement, supply chain innovation, ESG compliance, and governance in procurement. Each session is designed to equip attendees with practical insights and solutions to transform procurement operations and drive long-term business growth.ConclusionAPIS 2025 is a must-attend event for procurement professionals, industry leaders, and innovators looking to stay ahead in the fast-evolving procurement landscape. Join us in Kuala Lumpur to explore cutting-edge innovations, engage with procurement visionaries, and gain the tools needed to elevate procurement excellence across ASEAN.The ASEAN Procurement Innovation Summit & Awards (APIS) 2025 is organized by CT Event Asia, a leading provider of high-level industry events focused on innovation, procurement, and business transformation. With a mission to foster collaboration and drive impactful conversations, CT Event Asia connects procurement leaders, industry experts, and decision-makers to address the most critical challenges shaping the future of procurement.For more information, please contact:Amina KanteSenior Marketing ManagerCT Event AsiaPhone: +601161888699Email: aminak@cteventasia.com Website: https://www.aseanprocurementsummit.com/requestRegistration: www.aseanprocurementsummit.com/request  Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Apr 9, 2025 - (ACN Newswire via SeaPRwire.com) - SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a novel investigational therapy targeting the IL-25 (IL-17E) receptor pathway in moderate to severe atopic dermatitis (AD). SM17 uniquely binds to the co-receptor for IL-25, a key alarmin, and blocks downstream signaling – disrupting the inflammatory cascade driven by IL-25 engagement.SM17 Competitive Advantages:- First AD biologic with dual efficacy --- first and the only AD biologic that could reach both NRS-41 and EASI-752 responder rate over 60%3 simultaneously at end of treatment (EOT), comparing to marketed product.- Faster and deeper itch relief than anti-IL-4/13 agents4--- onset of anti-pruritus effect as early as Week 2 (SM17) vs Week 4~6 (other agents), over 90% of patients achieved NRS-4 (SM17) vs 30~40% of patients (other agents) at EOT.-  Safer than JAK inhibitors5 --- No serious adverse events (SAEs) nor drug related Grade 3 or above adverse events (AEs) reported， minimum risk of serious infections or major adverse cardiovascular events (MACE).1 NRS-4: a peak pruritus numeric rating scale (PP-NRS) weekly mean score with a ≥4-point reduction from baseline2 EASI-75: ≥75% reduction from baseline in Eczema Area and Severity Index (EASI) score3 SM17 ph1b NRS-4 responder rate:91.7%, EASI-75 responder rate 75.0%4 Dupixent@ Prescribing information, SOLO-1 & SOLO-2 studies5 RINVOQ@ Prescribing information, Measure Up 1 & Measure Up 2 studiesThis Phase1b study, which evaluated two doses level of SM17 (200mg and 600mg, respectively), met its primary endpoints manifested as the safety profiles in patients with moderate-to-severe AD by demonstrating that SM17 was well-tolerated with no serious adverse event (SAE) or treatment-related adverse events (TRAEs) with grade 3 or above. In terms of efficacy, this study met all the secondary endpoints assessing pruritus, skin healing and AD patients’ quality of life by demonstrating remarkable differences between SM17 treatment groups and placebo group.This study was a 16-week, randomized, placebo-controlled, double-blind study to assess the tolerability, safety and efficacy of SM17 monotherapy in 32 adults with moderate-to-severe AD, most of whom were previously inadequate responder to topical corticosteroids (TCS). Patients with a history of biologic (Dupilumab) or systemic Janus kinase (JAK) inhibitor medication (Upadacitinib) were also enrolled in the study.At week 12, 75.0% of patients（9 /12） in the higher dose group achieved ≥75% reduction from baseline in EASI-75, vs. 0.0% of patients in the placebo group, with difference of responder rate as 75.0%（95% CI：32.00~91.11）. In the lower dose group, 50.0% of patients (6/12) achieved EASI-75, a 50.0% difference vs. placebo (95%CI：9.27~74.62).In the higher dose group, 41.7% of patients (5/12) achieved a validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™) score of 0 (clear) or 1 (almost clear) with a ≥2-point reduction from baseline (vIGA-AD 0/1) at week 12, representing a 41.7% difference vs. placebo (95%CI: 2.28~68.05). In the lower dose group, 25.0% of patients (3/12) achieved this endpoint, a 25.0% difference vs. placebo (95%CI: -11.22~53.23).It is particularly noteworthy that 91.7% of patients (11/12) in the higher dose group achieved a peak pruritus numeric rating scale (PP-NRS) weekly mean score with a ≥4-point reduction from baseline (NRS-4) at week 12, vs. 0.0% of patients in the placebo group. Even in the lower dose group, 66.7% of patients (8/12) achieved this endpoint, remarkably different to that of the placebo group.With regard to the onset of action, SM17 showed obvious anti-pruritus effect as early as week 2 after the initial dose, in either the higher or the lower dose group. The altitude of improvement in pruritus for SM17 treatment groups increased alongside with dosing and reached a mean level of 68% and 57% reduction from baseline in PP-NRS score at week 12, for higher and lower dose groups, respectively, vs. 18% for placebo group. Improvement in pruritus was also maintained for both SM17 treatment groups until week 16, which was 6 weeks away from last dosing (week 10). Improvement in skin healing showed similar trends, with a mean level of 73% and 57% reduction from baseline in EASI score at week 12 for the 2 treatment groups，vs. a mean level of 42% reduction from baseline in placebo group.In addition, this Phase 1b study also met the endpoint of EASI 50 and EASI 90 at week 12, as well as superior improvement comparing to placebo in other skin healing measures as SCORAD and AD body surface area (BSA), or patients’ life quality questionnaire - Dermatology Life Quality Index (DLQI).Major efficacy endpoints results were summarized in the table below.EndpointsSM17 Higher dose (N=12)SM17 Lower dose (N=12)Placebo (N=12)EASI 50(%)Week1283.366.725.0Week1691.758.325.0EASI 75 (%)Week1275.0500.0Week1641.741.70.0EASI 90 (%)Week1241.716.70.0Week1641.741.70.0IGA 0/1 (%)Week1241.725.00.0Week1633.341.70.0NRS-4 (%)Week1291.766.70.0Week1675.058.325.0Safety findings were generally consistent with the safety profile of SM17 previously observed in US Phase 1 and China Phase 1a bridging study. The most frequent TEAEs (≥10%) in SM17 groups were nasopharyngitis and urinary tract infection，with the overall incidence rate difference between the treatment group and the placebo group being less than 5%.Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab, said, "SM17 has the potential to become a first- and best-in-class therapy for atopic dermatitis (AD), a market where a single transformative therapy can achieve multibillion-dollar (US) annual revenue. Pruritus is the primary concern for most of the patients with moderate-to-severe AD，and scratching behavior triggered by itch is likely the key driving factor in recurrent chronic inflammatory cycle in AD. With a favorable safety profile and skin clearance comparable to the most effective existing therapies, SM17 also delivers exceptional efficacy in itch relief – the most critical unmet need for patients.  By addressing these key gaps in current treatment options, SM17 is positioned to redefine the standard of care for this debilitating condition. We are accelerating our clinical programs and actively pursuing partnerships to maximize its global impact. Next, we anticipate initiating Phase 2 trials in adults with moderate-to-severe AD. Notably, preclinical studies have shown promising results for SM17 in treating other Type 2 allergic diseases such as asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and idiopathic pulmonary fibrosis (IPF). These findings suggest that SM17 could become a versatile therapeutic for a range of Th2-driven diseases, extending its potential beyond AD as a first- and best-in-class option."About Atopic Dermatitis MarketAtopic dermatitis (AD) is a chronic inflammatory skin disease with a complex pathogenesis involving genetic predisposition, skin barrier dysfunction, immune system dysregulation, and environmental factors. The immunological characteristics of AD are dominated by the Th2 axis, involving mediators such as TSLP, IL-4, IL-13, IL-5, IL-33, IL-31, OX40, and the JAK/STAT signaling pathway. AD typically begins in infancy, with about 50% of patients developing symptoms before the age of one. The disease follows a chronic and relapsing course.Epidemiological studies indicate that there are at least 230 million AD patients worldwide, with China having a substantial patient population exceeding 70 million, of which moderate-to-severe cases account for approximately 28%. In comparison, the U.S. has an estimated 16.5 million adult AD patients, with moderate-to-severe cases making up around 40%.According to Precedence Research, the global AD drug market was value at 13.62 billion in 2023 and is projected to reach 13.62 billion in 2023 and is projected to reach 31.44 billion by 2034. Current treatment options vary in efficacy and include topical medications (e.g., corticosteroids [TCS], calcineurin inhibitors [TCI]), oral antihistamines, and biologics, each with its own advantages and limitations.While conventional therapies like TCS, TCI, and oral antihistamines remain standard treatments, biologics such as dupilumab have significantly improved patients' quality of life. However, limitations such as slow onset, insufficient itch relief, and long-term safety concerns leave many patients' needs unmet. Another drug, the JAK inhibitor upadacitinib, faces safety-related challenges. In 2024, dupilumab's global sales surpassed $14 billion, highlighting the immense potential of the AD market and driving pharmaceutical companies to accelerate the development of differentiated therapies. Currently, competition in the AD field is primarily focused on target innovation: Among the top 10 AD clinical targets in China and globally, seven overlap, with IL-4Rα and JAK1 being the top two. In terms of clinical phases, only 14% of China's AD trials are in Phase 3 or later, compared to 23% globally (excluding Phase 2/3 trials), indicating that China's strategy remains largely fast-follow. Moreover, China's target landscape is more concentrated, with the top three targets (IL-4Rα, JAK1, and PDE4) accounting for 46% of clinical trials, whereas global AD clinical targets are more evenly distributed.About SM17SM17 is a novel, First-in-Class (FIC), humanized, IgG4-κ monoclonal antibody, which is a global first in-class monoclonal antibody drug targeting IL-25 receptor with the potential for treating AD, asthma, idiopathic pulmonary fibrosis and other immunological disorders. SM17 could suppress Type 2 helper T (Th2) immune responses by binding to IL-25 receptor (also known as IL-17RB) on Type 2 Innate Lymphoid cells (ILC2s) and Th2 cells, to block a cascade of responses induced by IL-25 and suppress the release of the downstream Th2 cytokines such as IL-4, IL-9 and IL-13. IL-25 is a critical cytokine classified as ‘‘alarmin’’, which has shown to be implicated in the pathogenesis of autoimmune and inflammatory skin diseases, especially in AD. Current approved therapies for AD, including biologics, can significantly improve eczema area and severity index (EASI) and patient’s quality of life, but they either are slow in response, especially in anti-pruritic effect, or have safety concerns. With the novel mechanism of action, SM17 hopefully will become a new and probably better treatment option for AD, which is fast in anti-pruritic response, effective in skin healing and safe, addressing the unmet medical needs not covered by current treatment modalities.About Differences in Targeting the Receptor (IL-25R) vs the Ligand (IL-25)Using AD as a model, stimulated skin will continuously release IL-25, and neutralizing IL-25 with antibodies does not instantly impart relief. SM17 uniquely blocks one of the IL-25 receptor subunits (IL-17RB) in a non-competitive manner. We have in-house data supporting that SM17 can block receptor signal transduction without affecting IL-25 engagement with the receptor, so SM17 can provide fast anti-pruritic and anti-inflammatory effects arising from IL-25/IL-25 receptor interactions.Additionally, the number of receptors on cell surface is limited, and if sufficient antibodies against the receptor are added and all receptors blocked, therapeutic response will persist regardless of the amount of IL-25 released. This is the case for SM17, which blocks the limited number of receptors on cell surface. Once fully occupied, it stops the signaling regardless of IL-25 levels. This allows a fast, long-lasting inhibition and avoids high-dose requirements.Contrarily, antibodies targeting IL-25 must neutralize the ligand directly, while AD skin continuously releases IL-25 such that anti-IL-25 therapies require high doses to “mop-up” all newly released IL-25. This delays itch and inflammation relief.About SinoMab BioScience LimitedSinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. SinoMab is headquartered in Hong Kong with its R&D base in Hong Kong and production base in mainland China. The Company's flagship product Suciraslimab (SM03) is a potential global first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. SM03 (Suciraslimab) has completed the Phase 3 clinical trial for RA in China and is pending NMPA’s marketing approval for RA in China. In addition, the Company possesses other potential first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren’s syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases with major unmet clinical needs.Media enquiriesStrategic Financial Relations LimitedVeron Ng  Tel: +852 2864 4831Phoenix Fung  Tel: +852 2114 4939Shannon Lei  Tel: +852 2114 2881Will Cheng  Tel: +852 2864 4894Email: sprg_sinomab@sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Apr 10, 2025 - (ACN Newswire via SeaPRwire.com) - How a small business presents and sells its offerings can be the difference between success and failure. GoDaddy has launched Show in Bio to help small businesses increase sales and stand out on social media.This affordable tool offers flexibility for small business owners not yet ready to build a website, enabling them to showcase their products or services on social media channels, including Instagram, TikTok, Facebook, X, Pinterest and LinkedIn, and interact with customers through channels like WhatsApp to close sales. Using artificial intelligence (AI) to quickly draft product information, such as name, description, and price, and create a personalized one-page sales catalogue in minutes, no technical skills are required to use the tool.Entrepreneurs who run their business on social media are more confident using AIResearch from GoDaddy’s 2025 Global Entrepreneurship Survey found over one in four (28%) of small business owners globally primarily run their business on social media. This shift in small business ownership to social-first entrepreneurs heightens the importance of how a small business sells online.  GoDaddy’s research has found these social-first entrepreneurs are younger, more optimistic about business performance and more confident in their ability to leverage AI for their business. This trend reveals not only the growth potential of social-first businesses, but also how technology – specifically AI – is a key enabler to innovate, scale and thrive.Start a business on social media with low spend and without the need to build a websiteShow in Bio allows entrepreneurs to start a business quickly with low spend, even validating a business idea before launching it. While perfect for small business owners who may not have yet built a website, the tool also supports domain integration, allowing those with an established online presence to use their own domain for a seamless branded experience.Key features and benefits include:Centralize Your Links – Put all your important content in one shareable link.Drive Engagement – Drive traffic to key offers and updates instantly by sharing your link in bio on social channels.Showcase Products – Create a captivating catalogue with images and videos directly on your page.Domain Integration – Use your own domain for a seamless and branded experience.Save Time with AI – Generate quality product information and profile bios fast, no tech skills required.“We’re supporting entrepreneurs to start their online business wherever it makes the most sense for them – including on social media,” said Selina Bieber, Vice President of International Markets at GoDaddy. “The rise of social media in the last 20-plus years has captured a significant share of internet activity, but it hasn’t diminished the need for businesses to have their own brand and their own identity.“Show in Bio is an enhanced link in bio solution built to support small businesses run on social media, directly addressing challenges such as driving traffic, lack of technical skills and setting up a website while simplifying social selling.”About GoDaddy GoDaddy helps millions of entrepreneurs globally start and scale their businesses. People come to GoDaddy to name their idea, build a website and logo, sell their products and services, and accept payments. GoDaddy Airo®, the company’s AI-powered experience, makes growing a small business faster and easier by helping them to get their idea online in minutes, drive traffic and boost sales. GoDaddy’s expert guides are available 24/7 to provide assistance. To learn more about the company, visit www.GoDaddy.com.Issued on behalf of GoDaddy.For more information, contact:Fekra Communicationsinfo@fekracomms.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HO CHI MINH CITY, VIETNAM, Apr 1, 2025 - (ACN Newswire via SeaPRwire.com) - analytica Vietnam 2025, Vietnam’s premier international trade fair for laboratory technology, analysis, biotechnology, and diagnostics, will officially open tomorrow at the Saigon Exhibition and Convention Center (SECC). Running from 2-4 April 2025, this highly anticipated exhibition promises to showcase groundbreaking innovations, cutting-edge technologies, and a dynamic conference program, bringing together over 300 exhibitors from 18 countries.Endorsed by the Ministry of Science and Technology in Vietnam and supported by the National Agency for Science and Technology Information and Statistics (NASTIS), the Center for Science and Technology Information (CESTI), the Key Laboratory of Analytical Technology for Environmental Quality and Food Safety Control (KLATEFOS), VNU, the Federal Ministry for Economic Affairs and Climate Action of Germany, and the Association of Small & Medium Enterprises (Singapore), analytica Vietnam continues to grow as the most influential laboratory event in Southeast Asia.In response to growing demand and expanding participation, analytica Vietnam introduces Hall A2 for the first time this year, adding 7,000 sqm of exhibition space in total, alongside the existing Hall A1. This expansion accommodates more exhibitors and innovations, reinforcing the event’s status as Southeast Asia’s leading laboratory exhibition.A Platform for Global Collaboration in the Laboratory Sector“The expansion with the new exhibition hall reflects our ongoing commitment to supporting the growth of the laboratory industry and fostering international collaboration,” said Mr. Michael Wilton, CEO of MMI Asia. “As Vietnam continues to emerge as a global hub for scientific and technological advancements, analytica Vietnam serves as a pivotal gateway for international companies seeking to enter this rapidly growing market, while providing local businesses access to world-class innovations.”This year, analytica Vietnam 2025 will feature an impressive lineup of exhibitors, including global leaders in laboratory technology, biotechnology, and analysis. The German Pavilion, Singapore Pavilion, and China Pavilion will be the largest ever at the event, underscoring the growing international interest in the Vietnamese and Southeast Asian laboratory markets. Additionally, delegations from Vietnam, Laos, Cambodia, Thailand, and Malaysia highlight the exhibition’s expanding international reach and its role as a key facilitator of cross-border partnerships.Pre-Show Press ConferenceBefore the official exhibition opening, a press conference was held on 31 March 2025 at the Crystal Palace Hotel, Ho Chi Minh City, where key industry players and media representatives gathered to discuss the significance of analytica Vietnam 2025.Key speakers included:- Mr. Vu Anh Tuan, Deputy Director, National Agency for Science and Technology Information and Statistics (NASTIS), who delivered the opening remarks, underscoring the event’s role in fostering technological innovation and international collaboration.- Mr. Michael Wilton, CEO of MMI Asia, who provided insights into analytica Vietnam’s evolution, emphasizing its expanding international reach and growing influence within the industry.- Representatives from leading exhibitors including ITS Vietnam, Waters, Kimteco Co., Ltd., and Hoa Viet Co., Ltd., who shared their experiences as returning participants, highlighting the strategic benefits of engaging with analytica Vietnam.Complementing the pre-show activities, analytica Vietnam 2025 organized exclusive Lab Tours on 31 March and 1 April 2025, granting the exhibitors behind-the-scenes access to some of Ho Chi Minh City’s most advanced laboratory facilities. These tours provided a unique opportunity to observe state-of-the-art research, laboratory operations, and cutting-edge technological applications in real-world settings.analytica Vietnam 2025 will feature a host of exciting new additions designed to engage attendees and provide valuable insights into the latest trends and innovations in the laboratory sector:- LIVE LAB: A first for Southeast Asia, the LIVE LAB is a fully operational laboratory integrated into the exhibition floor. Visitors will have the opportunity to witness live demonstrations of laboratory processes, interact with experts, and explore real-world applications of the latest technologies.- Startup Pavilion: Featuring emerging companies in the laboratory space, the Startup Pavilion will highlight new technologies and innovations shaping the future of the sector.- Lab Design and Construction Forum: This forum will delve into sustainable and efficient laboratory infrastructure, offering insights from industry leaders on the future of lab design.- Innovation Zone: A dedicated space showcasing breakthrough technologies transforming laboratory operations and industry practices.- Exclusive Lab Tours: Specially curated behind-the-scenes tours of leading research and testing facilities in Vietnam will offer participants a deeper understanding of local industry advancements.Additionally, the Academic Conference Program, one of the most anticipated segments of analytica Vietnam, will once again feature renowned thought leaders discussing critical industry trends, regulatory developments, and emerging research. Its strong reputation as a knowledge-sharing platform continues to attract top experts and professionals from around the world.Join the Industry’s Most Influential GatheringWith only one day left until the grand opening, excitement is building for analytica Vietnam 2025. The exhibition is set to provide an unparalleled platform for industry professionals, researchers, and business leaders to explore the latest innovations, exchange knowledge, and establish meaningful collaborations.Register now to be part of Vietnam’s premier laboratory technology event. For more details, visit www.analyticavietnam.comAbout analytica Vietnamanalytica Vietnam is the premier trade fair for laboratory technology, analysis, and biotechnology in Southeast Asia. Organized by Messe München, the event brings together industry professionals, researchers, and policymakers to showcase the latest technologies,exchange knowledge, and foster business collaborations. analytica Vietnam features an exhibition, conference, pre-event laboratory tours, buyer-seller programs, and networking opportunities, providing a comprehensive platform for the laboratory and biotechnology industries in the region. The upcoming edition is set to take place from April 2 to 4, 2025 at the SECC – Saigon Exhibition and Convention Center. More details can be found at https://www.analyticavietnam.com/.About analytica worldwideMesse München is the world’s leading trade fair organizer for laboratory technology, analysis and biotechnology. The international network of exhibitions includes analytica, analytica China, analytica Anacon India & India Lab Expo, analytica Vietnam and analytica Lab Africa. Additional information about these exhibitions and their programs of events is available at.About MMI Asia Pte LtdEstablished in 1992, MMI Asia is the wholly owned subsidiary and the regional headquarters of Messe München GMBH (MMG) and is one of the world largest and leading exhibition organizers. MMI Asia’s portfolio of events include editions of worldleading trade fairs from Munich – transport logistic & air cargo, analytica, ceramitec; as well as industry-specific events such as Glasstech and Fenestration Asia, Asia Climate Forum, and Singapore International Water Week. MMI Asia also provides consultancy in professional trade fair and conference management to government bodies, international trade and promotion organizations, and trade associations. For more information, please visit www.mmiasia.comAbout Messe MünchenAs one of the world’s leading trade fair organizers, Messe München presents the world of tomorrow at its about 90 trade fairs worldwide. These include twelve of the world’s leading trade fairs such as bauma, BAU, IFAT, electronica, and ISPO. Messe München’s portfolio comprises trade fairs for capital and consumer goods, as well as for new technologies. Together with its subsidiaries, it organizes trade fairs in China, India, Brazil, South Africa, Turkey, Singapore, Vietnam, Hong Kong, Thailand, and the U.S. With a network of more than 15 affiliated companies and almost 70 representations worldwide, Messe München is active in more than 130 countries. The more than 150 events held annually attract around 50,000 exhibitors and around three million visitors in Germany and abroad.Exhibition Contact:MMI Asia Pte. Ltd.Daniel ShiExhibition Directordaniel@mmiasia.com.sgPress Contact:MMI Asia Pte. Ltd.Joey NgMarketing Executivejoey@mmiasia.com.sg Copyright 2025 ACN Newswire via SeaPRwire.com.

JAKARTA, Apr 1, 2025 - (ACN Newswire via SeaPRwire.com) - Corinium Global Intelligence is excited to announce the return of CISO Indonesia 2025, the premier cybersecurity leadership conference, taking place on 28 May 2025 at the Pullman Thamrin CBD Jakarta. This highly anticipated event will serve as a dynamic platform for senior cybersecurity professionals to explore cutting-edge strategies, discuss pressing security challenges, and foster collaboration in an era of rapid digital transformation.With an agenda designed to address the evolving cyber threat landscape, CISO Indonesia 2025 will feature expert insights on:AI in cyber security – Navigating the double-edged sword of AI in cyber security – understanding the profound influence of AI on the offensive and defensive sides of cyber security.Government framework – Aligning cyber security strategies with government regulations and initiatives to effectively safeguard critical digital assets against emerging threats.Resilience for a digital future – Tackling the cyber security challenges related to emerging technologies, IoT, cloud security, and digital transformation in an increasingly connected world.Cyber security leadership – Addressing the talent shortage in cyber security by exploring initiatives to close the talent gap, including how AI can assist in this critical endeavor.Attendees will gain exclusive access to thought-provoking discussions led by over 20 distinguished speakers, representing some of the most influential voices in cybersecurity. The event will offer valuable networking opportunities, hands-on learning sessions, and actionable takeaways to help organisations stay ahead of emerging threats."As cyber threats continue to evolve, staying ahead requires more than just technology—it demands collaboration, knowledge-sharing, and strategic foresight. CISO Indonesia 2025 provides the ideal environment for security leaders to gain insights and forge connections that will help shape the future of cybersecurity,” said Eleen Meleng, Conference Director at Corinium Global Intelligence.This exclusive event is tailored for senior cybersecurity professionals, including CISOs, CIOs, CTOs, IT Directors, and Heads of Information Security from various industries. Those specialising in risk management, compliance, incident response, cloud security, and governance will find unparalleled value in attending.Registrations are now open! Secure your spot today and enjoy 20% off with the special discount code APAC20. Register now at: https://hubs.ly/Q03f2H8n0 . For additional event details, visit: ciso-id.coriniumintelligence.com.About Corinium IntelligenceCorinium Global Intelligence is a global leader in providing conferences, events, and content to the information and technology industries. With a focus on fostering collaboration and innovation, Corinium Global Intelligence brings together industry leaders to share insights, best practices, and strategies for success.For more information, please contactMoira Ungerleider, Marketing Manager at moira.ungerleider@coriniumgroup.com.  Copyright 2025 ACN Newswire via SeaPRwire.com.

New York, New York--(ACN Newswire via SeaPRwire.com - April 7, 2025) - Spiking, a leader in AI-driven financial technology, is thrilled to participate in IBM Z Day: Special Edition, a landmark virtual conference hosted by IBM on Tuesday, April 8, 2025, from 10:00 AM to 5:00 PM Eastern Time (ET). This complimentary one-day event invites technology enthusiasts, industry leaders, and innovators worldwide to witness the next era of enterprise computing and artificial intelligence, spotlighting Spiking's TradeGPT as a transformative force in capital markets.Event HighlightsGroundbreaking Keynote Announcement: At 10:00 AM ET, a live broadcast from New York City will unveil a major advancement in enterprise technology, including a new AI chip that Spiking's TradeGPT will leverage for unparalleled performance.Specialized Technical Tracks: Attendees can explore three cutting-edge tracks:IBM zNext: Discover the latest IBM mainframe, boasting up to 8x on-chip AI processors per core, enabling TradeGPT's unmatched scale, speed, and security.AI & Data: Learn how Spiking integrates advanced AI into mission-critical financial workloads without additional infrastructure.App Dev & IT Ops: See how AI-driven automation boosts productivity and efficiency, a cornerstone of Spiking's development strategy.Curated Experiential Journeys: Customize your experience with three paths:Security: Explore post-quantum encryption, critical for safeguarding TradeGPT's real-time financial insights.New to Z: Gain foundational knowledge about IBM Z, powering Spiking's enterprise ambitions.Developer: Dive into technical sessions tailored for developers enhancing platforms like TradeGPT.Earn Digital Credentials: Participants can earn up to four prestigious IBM digital skills badges, enhancing professional expertise.Dr. Clemen Chiang, CEO of Spiking, stated, "IBM Z Day: Special Edition is a defining moment for enterprise innovation, and we're proud to be at its forefront. Our LLM-based TradeGPT will harness the new AI chip unveiled on April 8, 2025, delivering unmatched speed and intelligence for real-time capital market decisions. This, alongside other surprises, positions Spiking to reshape how businesses leverage AI." Chiang's vision reflects Spiking's leadership in driving AI-powered transformation.Adam LG Ring, Global Head of the IBM Z Startup Community and Spiking's advisor, added, "As Spiking scales to volumes rivaling OpenAI, moving to an enterprise-scale solution with world-class security is both logical and essential. The latest IBM Z offerings, unveiled April 8, 2025, are cost-effective at scale-perfect timing for TradeGPT to lead the capital markets." Ring's endorsement highlights the strategic alignment between Spiking's goals and IBM's technology.Through IBM Z Day: Special Edition, Spiking joins IBM to offer a dynamic platform for connecting with global thought leaders, uncovering industry-defining trends, and showcasing innovations in AI, hybrid cloud, and post-quantum security. Tailored for all skill levels, this event is a must-attend for finance and tech professionals alike.Registration & AgendaRegister Now: Reserve your spot at https://ibm.biz/specialzday1Full Agenda: Explore the complete lineup of sessions and speakers at http://ibm.biz/agendazdayse2025Join Spiking and IBM on April 8, 2025, for a day of innovation, education, and networking as we unveil the future of enterprise computing and AI in capital markets.Media ContactNicole YeeMedia RelationsEmail: info@spiking.comPhone: 1-570-SPIKINGNote: All times are in Eastern Time (ET). Please adjust for your local time zone.About SpikingSpiking is a trailblazer in AI-driven financial technology, empowering businesses and investors with real-time, intelligent solutions for capital markets. Through its flagship product, TradeGPT, Spiking leverages cutting-edge AI to deliver unmatched performance and insights.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247585 Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Apr 8, 2025 - (ACN Newswire via SeaPRwire.com) - When it comes to symbolising eternal love, nothing captures the essence better than a diamond. ALUXE, Taiwan’s leading diamond and wedding jewellery brand, now brings its legacy of excellence to Singapore, offering an exquisite collection of certified diamonds at competitive prices.Instant Diamond SelectionFinding the perfect diamond has never been easier with ALUXE’s real-time selection of over 30,000 diamonds. Seamlessly integrated with global suppliers, every diamond is displayed with flawless brilliance details and a 360° high-resolution viewing experience. Customers can choose from a wide range of ready-to-go options or secure pre-orders with guaranteed delivery within two months.Competitive Pricing Without CompromiseALUXE eliminates unnecessary mark-ups by sourcing diamonds directly from the world’s top cutters. As one of Taiwan’s largest diamond importers, ALUXE ensures customers receive the highest quality at the best possible price, making premium diamonds more accessible than ever.Certified Excellence for Complete Peace of MindEvery ALUXE diamond comes with internationally recognised certification. Natural diamonds are graded by GIA, the gold standard in diamond evaluation, while lab-grown diamonds are certified by IGI. Additionally, the exclusive ALUXE Ultimate Diamond Report provides advanced scientific analysis of a diamond’s brilliance, ensuring only the finest stones make it to the collection.Fancy Cuts & Rare Colours for Distinctive EleganceBeyond classic round diamonds, ALUXE offers a stunning selection of fancy-cut and rare coloured diamonds, including pink, yellow, and blue hues, allowing customers to express their unique style.ROSÉ My Love – The Pink Diamond CollectionPink diamonds symbolise passion and rarity. ALUXE’s ROSÉ My Love collection features exquisite lab-grown pink diamonds, making this coveted gem more accessible. Ideal for engagements, anniversaries, or meaningful gifts, these diamonds capture the essence of romance.Lovers Collection – The Blue Diamond Wedding RingsBlue diamonds represent purity and everlasting love. The Lovers Collection showcases these rare gems in elegant wedding bands, complemented by platinum settings and inner sapphire accents, offering a timeless symbol of commitment.With decades of expertise, ALUXE is committed to helping couples find the perfect expression of love through meticulously crafted jewellery. Visit ALUXE in Singapore or explore our collection online to discover diamonds that make every love story shine.Discover more at www.aluxe.com/sg-en/About ALUXEALUXE is the first jewellery brand in Taiwan, embodying the perfect combination of happiness and jewellery. Starting as an online retailer, ALUXE's high-quality products and competitive prices gradually garnered more attention, which led to the opening of its first physical store in 2008 to offer even better products and services to customers around the world. ALUXE is currently present in Taiwan and Hong Kong, with Singapore’s flagship store located at ION Orchard and two other doors at the heartland areas.For more information, visit https://www.aluxe.com/sg-en/ FB: https://www.facebook.com/aluxe.sgIG: https://www.instagram.com/aluxe_sg/ALUXE LOCATIONSION Orchard2 Orchard Turn, ION Orchard #B2-63, Singapore 238801Tel: +65 6015 0798Opening Hours: 10:00 - 21:30JEM50 Jurong Gateway Road, JEM #01-55, Singapore 608549Tel: +65 6992 2589Opening Hours: 11:00 - 21:30Tampines 110 Tampines Central 1, Tampines 1 #01-27 & 28, Singapore 529536Tel: +65 6022 1715Opening Hours: 11:00 - 21:30 Copyright 2025 ACN Newswire via SeaPRwire.com.

Financial Highlights:- In 2024, the total revenue amounted to RMB5,261 million, representing a YoY increase of 25.1%  - The revenue of the 4Paradigm Sage AI Platform (the “Sage AI Platform”) business grew by 46.7% YoY to RMB3,676 million, accounting for 69.9% of the total revenue - The SHIFT Intelligent Solutions business recorded revenue of RMB1,022 million, accounting for 19.4% of the total revenue  - The revenue of the 4Paradigm SageGPT AIGS Services segment amounted to RMB563 million, accounting for 10.7% of the total revenue- Gross profit was RMB2,245 million, with a gross profit margin of 42.7%- The total R&D expenses reached RMB2,170 million, accounting for 41.2% of revenue- The annual loss attributable to the owners of the Company was RMB269 million, with a reduction of RMB640 million compared to the full year of 2023, narrowing by 70.4% YoY. This marks the fourth consecutive fiscal year of sequential loss reduction since 2021Operation Highlights:- In 2024, the number of lighthouse users served by the Company reached 161, a YoY increase of 16%. The average revenue per lighthouse user was RMB19 million, with a Net Dollar Expansion Rate (NDER) of 110% for lighthouse users in 2024- 4ParadigmSage: During the Reporting Period, the Company launched the vertical world model development and management platform, Sage AI Platform 5.0, and completed multiple minor version upgrades, achieving end-to-end capabilities across the computing layer, platform layer, model layer, and application layer- 4Paradigm SHIFT: During the Reporting Period, the Company launched multiple solutions targeting various application scenarios and continued to update and iterate the functionalities and effectiveness of existing solutions to meet enterprise requirements for accuracy, reliability, and real-time performance in different vertical scenarios- 4Paradigm AIGS: During the Reporting Period, the Company continued to upgrade and optimize the functionality and application performance of products, such as the enterprise software reconfiguration assistant AIGS Builder and the enterprise programming assistant AIGS CodeX, creating an enterprise-level “development assistant” that understands customers, businesses, knowledge and R&D, while enabling fast coding capabilitiesHONG KONG, Apr 1, 2025 - (ACN Newswire via SeaPRwire.com) - A leading enterprise AI software company - Beijing Fourth Paradigm Technology Co., Ltd. (“Fourth Paradigm” or the “Company”, Stock Code: 6682.HK) today announced the consolidated annual results for the year ended December 31, 2024 (the “Reporting Period”).In 2024, Fourth Paradigm achieved strong growth in its overall business. The Company’s total revenue reached RMB5,261 million, representing a YoY increase of 25.1%. Gross profit was RMB2,245 million, with a gross profit margin of 42.7%. The Company highly values technological R&D, and has clear profitability goals. During the Reporting Period, the R&D expenses reached RMB2,170 million, accounting for 41.2% of revenue. The annual loss attributable to the owners of the Company was RMB269 million, with a reduction of RMB640 million compared to the full year of 2023, narrowing by 70.4% YoY. This marks the fourth consecutive fiscal year of sequential loss reduction since 2021.In 2024, Fourth Paradigm committed to creating value for customers, continuously enhancing digital transformation experience for existing customers and increasing user stickiness. During the Reporting Period, the number of lighthouse users served by the Company reached 161, a YoY increase of 16%. The average revenue per lighthouse user was RMB19 million, with a Net Dollar Expansion Rate (NDER) of 110% for lighthouse users in 2024.Benefiting from the surge in AI market demand, the Company’s Sage AI Platform business achieved significant growth, driving steady performance improvement of core business. In March 2024, Fourth Paradigm launched Sage AI Platform 5.0, which integrates vertical world model development and management, enterprise AI agent application suites, GPU resource pooling and other end-to-end capabilities, supporting the large-scale production and application of vertical world models and enterprise AI agents, and continuously driving intelligent transformation and high-quality development across industries.Core business revenue increased by 46.7%, with scaled expansion driving rapid businessAs the core of the Fourth Paradigm’s all businesses, the 4Paradigm Sage AI Platform business achieved significant growth during the Reporting Period, with revenue reaching RMB3,676 million, representing a YoY increase of 46.7% and accounting for 69.9% of total revenue. Scale effects are deepening progressively.In 2024, Fourth Paradigm remained committed to technological innovation, comprehensively enhancing the capabilities of Sage AI Platform. On the basis of end-to-end capabilities across the computing layer, platform layer, model layer, and application layer, Sage AI Platform continued to optimize key capabilities such as AI agent and GPU resource pooling. Among these, AI agent further enhanced its ability to solve complex problems and improve execution accuracy, and developed the enterprise AI agent development platform that covers the entire lifecycle of AI agent design, development, debugging, deployment, operational analysis, and iterative optimization. This empowers enterprise developers to efficiently and scalably build business AI agents with cognitive, decision-making, and execution capabilities – all on demand. As a result, development cycles have been reduced by over 95% in most cases. The GPU resource pooling capability enables enterprises to achieve platform-level management of hardware clusters, on-demand allocation of computing resources, and rapid scheduling, helping to address challenges such as low utilization of heterogeneous computing resources and high costs of adapting large models to computing power. According to the latest report from the internationally authoritative research firm IDC, Fourth Paradigm has maintained its position as the leader in China’s machine learning platform market share for six consecutive years.While scaling its core business, Fourth Paradigm has also made steady progress in its two other major businesses – SHIFT Intelligent Solutions business and 4Paradigm AIGS service business, which provide strong support for the core business – Sage AI Platform, driving efficient growth across the overall business.During the Reporting Period, revenue from SHIFT Intelligent Solutions totaled RMB1,022 million, comprising 19.4% of the total revenue. This business is built on the Sage AI Platform, tailored to different industry business scenarios. These solutions enable Fourth Paradigm’s technology and capabilities to penetrate a wider range of industries and scenarios, addressing critical business challenges for traditional enterprises and driving digital and intelligent transformation across industries. Due to the impact of the business expansion strategy, the revenue from this business decreased by 20.3% YoY while the revenue from Sage AI Platform business achieved 46.7% YoY growth.In addition, the revenue from the 4Paradigm SageGPT AIGS Services business during the Reporting Period reached RMB563 million, accounting for 10.7% of the Company’s total revenue. This business provides efficient development tools and services based on generative AI for the Sage AI Platform business, enabling multi-fold increases in enterprise R&D productivity.“AI agent + Vertical World Model” dual-core architecture builds the AGI foundation, enabling continuous expansion of the business ecosystemIn recent years, the continuous advancement of generative AI technologies has accelerated progress toward Artificial General Intelligence (AGI), a consensus widely recognized across the industry. As an enterprise with over a decade of experience in the AI sector, Fourth Paradigm is committed to empowering industries through its core philosophy of “AI agent + Vertical World Model”, which uses AI agents to understand human needs and leveraging corresponding vertical world models to solve problems, while continuously enhancing their respective capabilities – will ultimately drive the realization of AGI.Over the past year, adhering to the philosophy of “AI agent + Vertical World Model”, Fourth Paradigm has collaborated with numerous industry partners and has successfully implemented hundreds of reliable and controllable enterprise-level AI agent applications, covering scenarios such as financial credit risk control, water and electricity equipment maintenance, hydrological data monitoring, chronic disease management, intelligent course learning, automotive manufacturing MES system management, fluid dynamics design, intelligent after-sales customer service and academic administration assistant, comprehensively driving the intelligent transformation for enterprises.At the same time, Fourth Paradigm, in collaboration with partners, has released several out-of-the-box user-level agent solutions, such as intelligent meeting solutions, intelligent mouse solutions, and desktop AI search tools. These solutions cover AI agent capabilities such as simultaneous interpretation, one-click translation, robotic assistants, AI writing, and intelligent cross-platform search, helping enterprise business personnel achieve a leap in daily work efficiency.In addition, since the advent of DeepSeek, the inference and deployment costs of large models have significantly decreased, catalyzing market demand across large model implementation, integrated solutions deployment, and on-device AI applications. Fourth Paradigm has rapidly iterated its technical capabilities and product adaptations to deliver high-value solutions addressing these market needs.In terms of integrated solutions, Fourth Paradigm launched the out-of-the-box SageOne IA large model inference integrated solution, which enables seamless switching between the full-capacity model and multiple distilled models while supporting mainstream large models. This increases GPU utilization by over 30% and improves inference performance by an average of 5-10 times. Furthermore, SageOne IA comes with a rich suite of AI applications, helping developers efficiently create enterprise-level generative AI applications.For on-device AI, Fourth Paradigm launched the ModelHub AIoT on-device inference solution. This solution allows users to easily deploy small-sized distilled models such as DeepSeek R1, Qwen 2.5, and Llama 2/3 series on on-device devices for offline operation. It also balances model compression and inference performance while addressing the complexities of deployment and optimization. In addition, the Company has further expanded these capabilities into the consumer electronics sector, delivering AI Agent solutions that integrate hardware and software. That empowers consumer electronics manufacturers to launch AI-enabled terminal products that resonate with their users.In terms of Strategic Outlooks, Dr. Dai Wenyuan, Chairman of the Board, Executive Director, Chief Executive Officer and General Manager of Beijing Fourth Paradigm Technology Co., Ltd. said, “In recent years, generative AI has gained widespread recognition globally. As an AI technology service provider with over a decade of experience in the enterprise service sector, we have a deeper and more accurate understanding of how to organically integrate these rapidly evolving AI technologies to empower our enterprise clients, create tangible business value, and deliver practical efficiency improvements for both enterprises and individuals. This aligns with our ultimate vision that has always guided our business – AI for Everyone. Looking ahead, we will build on our decade-long expertise in the enterprise service sector, look toward the broader AI market, and leverage our AI capabilities to transform all possible business domains. We believe that the convergence of these diverse capabilities will form the cornerstone for achieving AGI.” Copyright 2025 ACN Newswire via SeaPRwire.com.

Marrakech, Morocco, Apr 8, 2025 - (ACN Newswire via SeaPRwire.com) -  Morocco WEB3FEST GITEX Edition, a global conference series focused on technology and innovation in AI, Blockchain, and sustainability, organized by InactaVentures and co-hosted by The Hashgraph Association, being carried out in Marrakech, Morocco from April 14-16, 2025 is set to bring together the world’s foremost Web3 leaders, innovators, and investors at the intersection of technology, finance, and sustainability. Hosted in Marrakech during GITEX Africa, this premier event serves as a critical bridge linking the vibrant ecosystems of Africa, the Middle East, and Europe.With a strong commitment to advancingdecentralized technologies and sustainable innovation, Morocco WEB3FEST GITEX Edition is poised to drive meaningful dialogue and collaboration among industry pioneers, enterprises, and policymakers.What is the WEB3FEST?WEB3FEST is a global conference series focused on technology and innovation in AI, Blockchain and Sustainability. It serves as a vibrant hub where companies across the value chain – from agile startups to international corporations – converge to share ideas, build networks, and shape the future of the industry.Kamal Youssefi - President of The Hashgraph Association noted, “We are honored to be co- hosting the WEB3FEST in Morocco during GITEX Africa given that one of the aims of THA is to empower entrepreneurs, enterprises and governments with the technologies and knowhow needed to foray into Web3 while keepingsustainability at the heart of their endeavors. This is why Hedera network, considered one of the most sustainable in the world, is at the center of our conversations.”Ralf Glabischnig – Founder of Inacta Ventures, added, "Switzerland has always been a hub for Blockchaininnovation, and our Layer 1 technology is solving real-world challenges in developing countries. With Morocco as the perfect gateway to Africa, we are connecting European expertise with Africa’s immense potential for Blockchain adoption."Event Highlights:The Green Block TalksApril 14, 2025Sofitel Marrakech Palais ImperialA high-impact evening bringing together thought leaders and industry experts to discuss the role of AI and Web3 in driving sustainability. Featuring insightful panels, networking opportunities, and meaningful discussions.Featured Speakers:Ian Putter – Head of Blockchain COE, Standard BankTom Rieder – Director Marketplace, The Green BlockAbdelaziz Benyahya – Chief Transformation Officer, AXA MoroccoKamal Youssefi – President of The Board, The Hashgraph AssociationRalf Glabischnig – Founder, Inacta VenturesWEB3 Investor Dinner (Co-hosted by NEO AI)April 15, 2025Private Villa, MarrakechAn exclusive, invitation-only gathering for venture capitalists, fund managers, and private equity professionals.This intimate setting will facilitate high-level discussions on investment opportunities, portfolio strategies, and the evolving digital asset landscape.About the Organizer Inacta VenturesAt the helm of the WEB3 revolution, Inacta Ventures builds ecosystems, ventures, and smart capital strategies.With operations in the thriving Crypto Valley in Switzerland and the Crypto Oasis in the UAE, Inacta empowers over 100 portfolio companies and enterprises to scale groundbreaking WEB3 solutions.About the Co-Host The Hashgraph AssociationThe Hashgraph Association, a Swiss non-profit, drives global adoption of Hedera-powered solutions by funding innovation, training, and venture programs. It promotes economic inclusion and a digital future with a positive ESG impact. https://www.hashgraph.swiss/aboutRegistrationReserve your spot now and join the world’s brightest minds to shape the future of WEB3: Register HereFor more details, visit: web3fest.chContact:Fabio SchlafHead of Ecosystem Development Inacta Ventures & Crypto Oasis fabio.schlaf@inactaventures.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Apr 3, 2025 - (ACN Newswire via SeaPRwire.com) - JBM (Healthcare) Limited (“JBM Healthcare”; Stock Code: 2161, together with its subsidiaries, the “Group”), a leading branded healthcare products marketer and distributor in Hong Kong, announced today that it has acquired a 90% stake in Tin Hee Tong Medicine Factory, Limited (“Tin Hee Tong”,), at a total consideration of HK$171.0 million. Tin Hee Tong has now become a non-wholly owned subsidiary of JBM Healthcare.Strengthening the Portfolio with a Trusted Heritage BrandTin Hee Tong’s flagship product, Tin Hee Tong Tin Hee Pills, has a rich legacy and strong brand recognition across Hong Kong and Mainland China, particularly in Guangdong Province. The product is well formulated for regulating the female menstrual cycle, promoting reproductive health, and enhancing blood circulation for a radiant complexion. Tin Hee Tong Tin Hee Pills is a highly trusted brand for gynecological well-being among female consumers. Recognising its distinctive market position and long-term growth potential, the Group sees this acquisition as a valuable strategic fit for its proprietary Chinese medicines portfolio.Unlocking Growth Potential & SynergiesThe acquisition presents a compelling opportunity to expand the Group’s portfolio of proprietary Chinese medicines and accelerate its growth strategy. By integrating this iconic brand into its existing lineup, the Group is well-positioned to capitalise on rising consumer demand for holistic healthcare solutions.To maximise the brand’s potential, the Group plans to launch a comprehensive marketing campaign, leveraging its extensive expertise in brand management and revitalisation to boost consumer awareness and engagement. Additionally, the Group will expand distribution networks to capitalise on new market opportunities and customer segments. By combining the complementary strengths of both businesses, the acquisition is expected to generate significant synergies, reinforcing the Group’s strategy of acquiring assets that align with its long-term vision and create shareholders’ value.Proven Track Record in Brand RevitalisationThe Group has a proven track record of revitalising heritage proprietary medicines brands, effectively transforming legacy products into prominent market players. Its portfolio includes iconic brands such as Po Chai Pills — a market leader in proprietary Chinese gastrointestinal medicines, Ho Chai Kung — a widely recognised household name in the OTC pain killer category, and Flying Eagle Woodlok Oil — a rejuvenated brand in the traditional Chinese medicated oil sector, driven by creative advertising that blends Hong Kong nostalgia with broad consumer appeal.Through strategic brand revitalisation, omni-channel expansion, and digitally driven consumer engagement strategies, the Group has successfully transformed heritage brands into contemporary wellness solutions that resonate with both loyal customers and the younger,  generations. With Tin Hee Tong Tin Hee Pills, JBM Healthcare is set to reinvigorate this trusted brand and expand its market presence.Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare said, “The acquisition of Tin Hee Tong represents a pivotal step in strengthening our leadership in the proprietary Chinese medicines sector. With its rich heritage and strong recognition, Tin Hee Tong Tin Hee Pills is a highly complementary addition to our portfolio. Drawing on our proven brand revitalisation expertise, we are confident in unlocking its full growth potential and delivering long-term value to our shareholders.”About JBM (Healthcare) Limited; Stock Code: 2161)JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia, and other select countries. The Group is a distinctive player in the sector with marketing expertise and heritage in pharmaceuticals that prioritises product efficacy and quality to meet consumers' healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines, and health and wellness products, which include well-recognised household brands such as Po Chai Pills , Ho Chai Kung Tji Thung San , Tin Hee Tong Tin Hee Pills , Flying Eagle Woodlok Oil , Tong Tai Chung Woodlok Oil , Shiling Oil , Konsodona Medicated Oil , Contractubex  and Mederma for Kids . JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

TAIPEI, TW, Apr 8, 2025 - (ACN Newswire via SeaPRwire.com) - In a feature recently published by The Icons, Taiwanese artist Grace Tan is recognized for redefining the language of traditional ink art through a contemporary, multi-sensory approach. A master of calligraphy and seal carving, Tan seamlessly blends Eastern aesthetics with Western structures, transforming brush, ink, and rhythm into a vivid cross-cultural dialogue.Rooted in the rich cultural heritage of Taiwan, Grace Tan views art as a universal language - one that speaks beyond technique and form. "Art is the language of the soul," she explains. "Its power lies in whether it can create a resonance - a rhythm that connects deeply with others."Her artistic practice is deeply influenced by music, particularly her study of the pipa, a traditional Chinese instrument. She describes her brushwork as a visual form of music, where ink density, stroke pressure, and spatial pauses mirror tempo, pitch, and silence in a musical composition. Her compositions are at once lyrical and structured, poetic yet dynamic.Through innovative techniques such as layering, geometry, and the use of lightboxes, Tan creates an immersive visual-musical experience. Her artworks are not static; they shift in response to lighting and perspective, offering viewers a real-time encounter with rhythm, space, and emotion.As a Taiwanese artist active on the international stage, Grace Tan has exhibited in France, the United States, Japan, and South Korea. Her works are housed in the permanent collections of the World Bank Headquarters, the American Academy of Asian Culture, the San Francisco Public Library, and the University of Cyprus - testament to her growing global impact.Grace Tan composes with ink and lets her lines sing, transforming calligraphy, seal carving, and visual art into vessels of musical expression. From the interplay of geometry and colour, to the rhythmic flow of brushstrokes and the carefully composed cadence within her seal designs, her work reflects a profound exploration of "rhythmic writing." The dryness or fluidity of ink, the tension and release of each line, and the thoughtful use of negative space resemble the dynamics and pauses found in musical composition - all weaving together into her own distinctive artistic tapestry. (Photography: Grace Tan)Her artistic voice carries particular resonance for European audiences, who appreciate her thoughtful fusion of East and West. By combining the introspective stillness of Eastern philosophy with the expressive freedom of contemporary Western art, she opens a space for cultural reflection and connection.Grace Tan's work is not just a celebration of tradition, but a reimagining of it - offering a vision of art that transcends borders and speaks to the shared human experience. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Apr 7, 2025 - (ACN Newswire via SeaPRwire.com) - TVS Motor Company (TVSM), a leading global manufacturer of two and three-wheelers, is set to strengthen its electric vehicle (EV) presence in Southeast Asia through the integration of ION Mobility’s assets, intellectual property, and talent into its operations. Southeast Asia represents one of the world’s fastest-growing regions for motorbike usage, offering a significant opportunity for expansion.TVSM has been a strategic investor in ION Mobility, a full-stack EV company known for its robust in-house capabilities across industrial and product design, mechanical and electrical engineering, embedded and power electronics, firmware, software, and supply chain solutions. This integration, combined with TVSM’s deep expertise in electric mobility, marks a major step toward unlocking new possibilities in the region.Commenting on the development, Sharad Mohan Mishra, President Group Strategy, TVS Motor Company, said: “We were an early strategic investor in ION Mobility, attracted by their focus on delivering smart, sustainable, and exciting mobility solutions for ASEAN markets. Our ‘Reimagine 2030’ vision strongly aligned with their mission. With the acquisition of ION Mobility’s assets, IP and core team, we are thrilled to bring their entrepreneurial energy, design thinking and engineering strength into TVSM. Combined with our R&D depth, quality systems, and manufacturing scale, this partnership positions us to accelerate market penetration and grow our share across Southeast Asia.”TVS Motor is already a formidable player in the global EV landscape, with nearly 600,000 customers choosing its flagship electric scooter, TVS iQube. The company has developed end-to-end in-house capabilities across EV components - battery systems, battery management, vehicle control units, and connected platforms - and holds more than 650 patents in the EV domain.Earlier this week, TVS Motor Company announced that its wholly owned subsidiary TVS Motor (Singapore) Pte Ltd acquired select assets from ION Mobility and also divested its stake in the company. Following this move, James Chan, Founder and CEO of ION Mobility, has joined TVS Motor Company as Senior Vice President. He will lead TVSM’s business across ASEAN while also spearheading the development and launch of the M1-S electric mobility platform. The M1-S is already generating strong interest in ASEAN markets for its striking design, impressive range, agile acceleration, and suitability for daily commutes.About TVS Motor CompanyTVS Motor Company (BSE:532343 and NSE: TVSMOTOR) is a reputed two and three-wheeler manufacturer globally, championing progress through sustainable mobility with four state-of-the-art manufacturing facilities located in India and Indonesia. Rooted in our 100-year legacy of trust, value, and passion for customers, it takes pride in making internationally accepted products of the highest quality through innovative and sustainable processes. TVS Motor is the only two-wheeler company to have won the prestigious Deming Prize. Our products lead in their respective categories in the J.D. Power IQS and APEAL surveys. We have been ranked No. 1 Company in the J.D. Power Customer Service Satisfaction Survey for four consecutive years. Our group company Norton Motorcycles, based in the United Kingdom, is one of the most emotive motorcycle brands in the world. Our subsidiaries in the personal e-mobility space, Swiss E-Mobility Group (SEMG) and EGO Movement have a leading position in the e-bike market in Switzerland. TVS Motor Company endeavours to deliver the most superior customer experience across 80 countries in which we operate.For more information, please visit www.tvsmotor.com or write to corpcom@tvsmotor.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Mar 31, 2025 - (ACN Newswire via SeaPRwire.com) - Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year ended December 31, 2024 (the "Reporting Period"). During the year, the Group adhered to its overall business philosophy of “in-depth services and lean operations”, promoted development with innovation, deepened integrated collaboration among “government, industry, academy, research, medicine, application”, accelerated digital application of “AI + medical care”, continuously strengthened refined management, and reduced cost and improved efficiency, demonstrating strong operational resilience.In 2024, due to changes in the macro-environment, intensified competition in the industry as well as its strategic decision to optimize customer structure and product mix, the Group’s performance was temporarily affected. However, relying on its customer-oriented, innovative and coordinated development system, the Group achieved many breakthroughs in product innovation, model innovation, AI + medical digital intelligence and other aspects. The joint construction business with medical institution alliances remained its largest business segment, which accounted for 53.0% of the total revenue, representing an increase of 4.7 percentage points as compared to the same period of the previous year. In addition, featured products in the infection segment achieved rapid growth, laying a solid foundation for the segment’s long-term development. During the Reporting Period, the Group’s total revenue reached RMB711.9 million.Diagnostic testing for medical institution alliances was developing healthily   In-depth service empowers customersYunkang is committed to developing an innovative service mode for joint construction of medical institution alliances with “professionalism as the foundation, standardization as the core, digital intelligence as the means, synergization as the goal”. At present, the Group is providing medical technical service solutions to over 1,500 medical institutions in collaboration with medical institution alliances at over 430 on-site diagnostic centers of the alliances to meet their core demands. Through close collaboration – mutual recognition of testing results – with leading regional medical institutions, the Group has helped improve overall regional medical and treatment levels, helping hospitals build specialty departments, improving the efficiency of hierarchical diagnosis and treatment, promoting scientific research and cooperation, etc., thereby providing the public with higher-quality and more efficient diagnosis and treatment services. Dedicated to vigorously driving medical reform in China, during the Reporting Period, Yunkang teamed up with leading provincial-level hospitals, and regional county-level general hospitals to jointly build medical institution alliances to actively promote the construction of medical institution alliances as the bridge that connects the regional testing centers and partner hospitals. Customers are provided with “3+N” tumor, infection, reproductive genetics and +N technical system support, and also support from the in-depth service system, including the operation of diagnostic centers under regional medical institution alliances, access to new technologies or new products, construction services for digital specialty departments, medical cold chain logistics services, quality control services and supply chain services, all in-depth services for empowering demand and the long-term development of hospitals.Focus on “clinical demands”   Joint innovation for diagnostic testing achieved remarkable resultsAdhering to the “clinical demands”-oriented service concept, the Group has built a series of high-tech platforms, including high-throughput sequencing, gene chip, high-sensitivity PCR, protein spectrometry, cytogenetics, digital remote pathology, and ultra-micro pathology. During the Reporting Period, the Group introduced nearly 800 new testing items and provided about 3,800 clinical testing items, and more than 10 million specimens were tested for the year. In terms of precision diagnosis and treatment, the Group carried out more than 500 precision diagnosis services using cutting-edge technologies such as high-throughput sequencing, and protein spectrometry, covering five medical fields including infectious diseases, reproductive genetics, solid tumors, blood diseases, and personalized medicine. During the Reporting Period, the Group focused on the construction and development of 58 new items in such fields including infection, tumor, rare genetic diseases and personalized medicine, providing medical institutions nationwide with a more comprehensive range of precision diagnosis solutions to drive the embrace and development of precision medicine. During the Reporting Period, revenue from special testing items increased significantly year-on-year, accounting for a larger percentage of the Group’s overall revenue.The Group has a first-of-its-kind “joint innovation platform for diagnostic testing”, which has played a vital role in expanding its business and boosting competitiveness of its products. Constantly exploring and putting ideas into practice, the Group and dozens of top medical institutions across the country have pursued joint innovation for diagnostic testing and successfully developed more than 10 testing products for different infection syndromes in various fields such as respiratory tract infections and central nervous system infections.Digital application of “AI + medical care” leads the industryThe Group has launched and continuously upgraded its top 10 digital “cloud” systems, covering core areas such as laboratory operations, sales management, human resources, staff training, and customer services. At the same time, it has integrated AI technology into its “cloud” systems to create a one-stop intelligent medical diagnostic solution covering from “sample collection” to “report delivery”, which was comprehensively applied across its multi-technology platforms in medical laboratories, with the core concepts of “Internet+” and “precision diagnosis” to create a series of intelligent diagnostic platforms. In the Reporting Period, the Group’s self-developed digital IT platform with full intellectual property rights – the remote pathology consultation platform – covered over 800 medical testing items, assisting nearly 300 medical institutions nationwide in enhancing their pathology diagnostic capabilities and benefiting more than 200 million patients in rural areas.Regarding the application of AI-assisted diagnosis, the Group adheres to the strategy of “introducing one item once it is mature” and closely follows industry development trends. It has introduced items such as pathological DNA polyploid AI-assisted diagnosis, cervical liquid-based cell AI-assisted diagnosis, and chromosome AI analysis, all proven effective and have greatly enhanced diagnostic efficiency. During the Reporting Period, the Group focused on the field of infectious diseases and developed its first infectious disease data product, the “Yunkang Respiratory Pathogen Detection Positivity Rate Analysis Report”. The product officially obtained data product certification and was listed on the Guangzhou Data Exchange in January 2025, marking a milestone step for the Group in the field of compliant data transactions, effectively unlocking data value. Currently, having access to the DeepSeek large model, the Group aims to achieve comprehensive innovation in medical testing and diagnostics through inclusive technology, precision service and intelligent management.Collaborative and integrated development of “government, industry, academy, research, medicine, application” to facilitate industrial upgradeDuring the Year, the Group collaborated with various institutions to facilitate industrial upgrade based on a unique innovative industrial model, including:- Collaboration with The People’s Government of Ouhai, Wenzhou City and Wenzhou Medical University’s core areas in biomedical industry to promote construction of a number of key projects including a joint innovation and transformation platform, a public service platform, a medical big data research platform, a regional diagnostic sharing center and a training base for innovative talent, to the end of facilitating quick transformation of scientific research results for industrial applications;- Collaboration with The Zhangjiang Research Institute of Fudan University to jointly establish a “Collaborative Innovation and Transformation Center” to promote innovation and transformation of results of medical diagnostic technology application;- Collaboration with The Central University of Finance and Economics, Greater Bay Area Research Institute to jointly build an industry-education fusion talent cultivation highland and an industry aggregation and incubation platform.The strategy for sustainable development drives long-term valueWhile vigorously driving business development, Yunkang has consistently viewed sustainable development as a core strategy of the Group, committed to promoting the green transformation of the healthcare industry through innovative technologies and in-depth services. The Group engaged in environmental protection efforts such as energy conservation, emission reduction, and resource recycling in its operations, while also launched various charitable initiatives, including charitable clinical diagnostic activities, health checkup services for the well-being of the community, and health seminars, to give back to society by making use of its professional advantages.  Looking ahead, Yunkang will continue to make progress in ESG and step up our efforts in such areas as environmental policy and management, Scope 3 emissions, climate governance, climate performance indicators, climate scenario analysis, carbon reduction targets, and net-zero emissions commitment, all of which will help us realize economic, environmental and social benefits.Future prospectsChina has continued to promote expansion and downward penetration of the country’s high-quality medical resources, fostering a balanced regional layout and stepping up the construction of a hierarchical diagnosis and treatment system, conducive to establishing close-knit medical institution alliances. China’s Laboratory Developed Testing methods (LDT) pilots have steady and notable progress, leading to market growth for precision medicine development. In addition, in-depth integration of AI technology with the healthcare industry will become an important driving force for fine industry segments to embark on digital intelligence transformation and upgrade. Looking ahead, Yunkang will continue to align with national policies, seize the latest industry development opportunities, and continue to strengthen clinical-empowered value, and constantly explore and deepen the two new “product innovation + model innovation” model with customers in mind and to ensure residents can better benefit from its medical achievements.Yunkang Group Limited（Stock Code：2325）Yunkang Group is a leading medical operation service provider in China, which started to provide standardized medical diagnostic services to medical institutions at all levels as early as 2008. Leveraging its own professional diagnostic capabilities and the nationwide service network of integrated healthcare systems, Yunkang has gradually grown to become a medical operation service platform. Meanwhile, Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services which are diagnostic outsourcing services and diagnostic testing services for medical institution alliances. Yunkang provides diagnostic services through on-site diagnostic centers to collaborative hospitals in the integrated healthcare systems in China and assists them in improving their clinical diagnosis capabilities through co-developing diagnostic centers. As of today, Yunkang has successfully provided professional services to 430+ on-site diagnostic centers. As of December 31, 2024, the hospitals we collaborated with were located across 31 provinces and municipalities in China. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Apr 4, 2025 - (ACN Newswire via SeaPRwire.com) - Connect Marketplace Hong Kong (CMHK) successfully concluded its preview event in APAC in 2025, marking a significant milestone in fostering business collaboration within the MICE industry. Held from 19-21 March 2025, the event successfully brought together over 4,000 industry professionals, along with more than 60 exhibitors from over 30 countries and regions. It focused on creating an invaluable platform for networking and business development.Margaret Ma Connolly, president and CEO of Informa Markets in Asia, highlighted the event’s role in driving transformation within the MICE industry. “The launch of Connect Marketplace Hong Kong is more than just a new event. It's a testament to our belief in Hong Kong as the ultimate MICE destination. Here at Connect Marketplace Hong Kong, we’re not just discussing the future of business events – we’re actively shaping it, fostering connections that transcend borders and drive economic growth across Asia and beyond” she said.Connect Marketplace Hong Kong excelled as a premier platform for business collaboration, featuring the Hosted Buyer Programme, which brought together around 450 international decision-makers and facilitated close to 1,300 business organised through its innovative one-on-one meeting initiatives.Additionally, conference sessions and forums addressed key industry topics, from sustainability to cutting edge MICE solutions. A series of networking opportunities, including Horse Racing Night, Gala Dinner and a Familiarization Trip to Macau further strengthened interactions among global industry players.Janice Lee, Senior Portfolio Director of Connect Marketplace Hong Kong, expressed excitement for future growth: “This is a remarkable achievement! I have witnessed the spirit of Informa unfold over four months of hard work, culminating in around 4,000 attendees at the show. This success gives us great confidence as we look ahead to the next edition of CMHK in 2026.” The next edition of Connect Marketplace Hong Kong is scheduled for 18-19 March 2026.About Informa MarketsInforma Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.For media enquiries, please contact: cheenie.so@informa.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HIGHLIGHTS:- During the Reporting Period, the Group’s gross billings amounted to approximately RMB3,505.9 million, representing an increase of approximately 49.3% from approximately RMB2,347.7 million for the Corresponding Period.- The total revenue of the Group was approximately RMB2,306.0 million, representing an increase of approximately 17.3% compared to approximately RMB1,965.4 million for the Corresponding Period.- The profit attributable to Shareholders of the Group was approximately RMB272.4 million, representing an increase of approximately 42.8% from approximately RMB190.7 million for the Corresponding Period.- The Group’s operating cash flow (net inflow) was approximately RMB1,627.8 million, representing an increase of approximately 266.6% as compared to approximately RMB444.0 million for the Corresponding Period.- Taking into account the financial and cash flow positions of the Group, the Board recommends the payment of a final dividend of approximately HKD148.0 million for the year ended December 31, 2024, representing HKD0.33 per share (in cash), and the proposed final dividend is subject to consideration and approval by Shareholders at the AGM.HONG KONG, Apr 4, 2025 - (JCN Newswire via SeaPRwire.com) - 28 March, JF SmartInvest Holdings Ltd(the “Company” ; together with its subsidiaries, the "Group" or “we”) is pleased to announce its consolidated annual results for the year ended December 31, 2024 (the “Reporting Period”). During the Reporting Period, the Company realized a revenue of approximately RMB2,306.0 million, representing a growth of approximately 17.3% from the Corresponding Period. Profit attributable to Shareholders amounted to approximately RMB272.4 million, representing an increase of 42.8% over the Corresponding Period. In addition, our operating cash flow was strong. We had a net inflow of approximately RMB1,627.8 million which represented a significant year-on-year growth of 266.6%, fully demonstrating the effective strategy execution and high market adaptability of the Company.Developed a multi-dimensional product structure to promote business and revenue diversificationDuring the Reporting Period, on top of integrating and improving our existing products, we launched the industry’s first-ever stock learning machine and enriched our small-amount series product matrix for the promotion of revenue diversification. We have formed four main product lines currently, namely “Stock Navigator Series and Super Investor” , “Enjoy-Stock Pad”, “Jiuyao Stocks” and “SmartInvest App” (App). We aim to serve a wider spectrum of customers in a more effective manner by capitalizing on the synergies of these product lines.In order to meet users’ needs, we launched the first “Enjoy-Stock Pad (Starter Edition)” in July to fill the market gap for professional stock learning products. The Company expected that the launch of this product would create a dedicated learning platform for investors, actively fulfil corporate social responsibilities and deepen the inclusive financial education practice. In the meantime, we launched nearly 30 lightweight products to achieve product scalability and standardization, which allowed us to meet the diverse users’ needs and fully explore long-tail customers. During the Reporting Period, our small-amount series products were used by our subscriber customers for more than 2.203 million times.Adherence to pursuing “technological research + investment research” dual-driver strategy, deepening AI technology for full empowerment for the Company’s business and practical applicationImplementing our “technology + investment research” dual-driver strategy, we further increased our R&D investment, explored the empowerment and application of AI and other frontier technologies to the Company’s product offerings, business operations and operational management. With focus on the “buyer-side investment advisory” service, we strengthened our “1+N” investment research system to fully penetrate our investment research into businesses and processes, so as to professionally support our customers in creating long-term value.We continuously strengthened our R&D capabilities and investment: During the Reporting Period, we invested approximately RMB319 million in R&D activities, representing an increase of 10.9% over the Corresponding Period. Such R&D investment accounted for approximately 13.8% of the Company’s total revenue. In addition, as of the end of the Reporting Period, we had 136 software copyrights and patents on product features, big data and AI, that was 52 more than last year. What is noteworthy is that during the Reporting Period, we became a member of the Chinese Association for Artificial Intelligence (CAAI), signifying that the Company has been recognized for its core AI R&D technologies and achievements in the financial sector.We explored the all-round empowerment of AI and other frontier technologies to the Company’s product offerings, business operations and operational management. In terms of empowering our product offerings, we launched “FinSphere Agent”, a new-generation conversational stock investing assistant, and “FinSphere Report”, an intelligent investment research product. They provide deep-thinking intelligent conversational investment advisory services and intelligent research report generation and explanation services. We continuously upgraded our digital investment robo-advisor “Jiu Ge”, served approximately 472,000 customers, with total services reaching 32.407 million times, during the Reporting Period. In terms of empowering our business operations, we deployed our “AI Marketing Partners” and “AI Live Replay Summaries” which enabled us to achieve full-process coverage of text generation and pitch recommendations that doubled our communication efficiency. In terms of empowering our compliance management: The Company developed the intelligent compliance management solution 3.0, with which, our “AI Monitoring Officer” has conducted approximately 1.6 billion monitoring tasks and our “AI Inspection Officer” has assisted in over 10 million review tasks, achieving a coverage rate of 98%.We focused on “buyer-side investment advisory” and emphasized the application of our investment research. In the single month of December, our professional stock review programs output an average of approximately 22 shows per day, with a total duration of nearly 13 hours; we engaged active interactions with investors and answered their questions. The average number of inquiries per day exceeded 2,500. Our JF Financial Research Institute has designed more than 218 sets of self-developed signature courses, with a total of more than 1,300 sessions and a total of over 12,000 minutes, further improving the system of providing courses on our Stock Learning Machine.Establishment of quality traffic system to achieve precise expansion of new customer baseWe established quality traffic system and continued to expand our presence on platforms. During the Reporting Period, apart from our established presence on Douyin and WeChat Channels, we explored Kuai and tapped into platforms such as Xiaohongshu and Bilibili, to achieve high accessibility to customers, increase our brand exposure, optimize our live broadcast efficiency and enhance viewers’ experience through short video + live broadcast approach. The live broadcasts lasted over 49,800 hours cumulatively with 26,500 sessions, representing a growth of over 110% from the Corresponding Period. During the Reporting Period, we operated 152 new MCN accounts on different internet platforms. As of December 31, 2024, we had 526 MCN accounts and attracted approximately 50.05 million followers, as compared to approximately 11.15 million followers in the Corresponding Period.At the same period, we actively promoted popular investor education and enhanced brand influence. At the National Investor Protection Publicity Day on May 15, we organized the “Shareholders Are Here” event jointly with Everbright Securities to attract investors’ participation in the education on rational investing through short videos and live broadcasts on all of the Company’s platforms, together with the active promotion by traditional media such as Hubei TV and China Business Network (CBN). As of December 31, 2024, we have exclusively sponsored CBN’s live broadcast of the Berkshire Hathaway Annual Shareholders Meeting for the fifth consecutive year. We produced the live broadcast program “Buffett and Seven Lunches”, which recorded a total online viewership of nearly 227 million.Business outlookThe chairman of the Board and chief executive officer of JF SmartInvest Holdings Ltd, Mr. Chen Wenbin said: "We will adhere to our principles of rational investing, value investing and long-term investing to help customers induce right investing concepts, practice investor education, fulfil corporate social responsibility and commit ourselves to promoting healthy development of the capital market in the long run. Looking forward to 2025, we, as a next-generation stock investing assistant, will continue to strengthen our competitiveness, solidify our market leadership and strive to make investing and wealth management easier yet more professional, and enhance the happiness of investing and wealth management. "About JF SmartInvest Holdings Ltd (Stock Code: 9636)JF SmartInvest Holdings Ltd is a new generation stock investment assistant. The Company is engaged in the provision of equity investment instruments, securities investment advisory, investor education and other services to individual investors. The products include stock quote software, stock learning machine, Stock Navigator, Super Investor and Jiuyao Stocks. The Company adopts the technology + investment research model, develops JF Robo-Advisor, FinSphere Agent, FinSphere Report and other products based on artificial intelligence (AI) and big data technology, which are applied to the industry in terms of innovative practice and scenario application.For enquiries, please contact:Financial PR (HK) LimitedEmail: ir@financialpr.hkTel: 852 2610 0846Fax: 852 2610 0842 Copyright 2025 ACN Newswire via SeaPRwire.com.

Kuala Lumpur/Bangkok/Singapore , Apr 3, 2025 - (ACN Newswire via SeaPRwire.com) - India is emerging as the world’s next manufacturing giant—yet global corporations still stumble at the entrance. Despite its $7.5 trillion growth trajectory, cost advantages, and policy incentives, there are still several obstacles in the way of building a long-lasting presence in India. A recent whitepaper titled “Why Do Global Manufacturers Struggle with India Market Entry” offers a data-driven blueprint for overcoming regulatory, supply chain, and regulatory obstacles in one of the world’s complex but most promising economies.Regional companies aiming to expand into India can find a powerful roadmap in SRKay Consulting Group’s latest release, “Why Do Global Manufacturers Struggle with India Market Entry” This comprehensive publication outlines the key challenges that often derail even the most experienced players—including regulatory red tape, infrastructure hurdles, intellectual property risks, pricing pressures, and workforce acquisition difficulties.The report dives deep into the root causes behind these obstacles, from fragmented supply chains to complex compliance landscapes, and presents a structured, four-pillar India entry strategy. Covering insights across seven key sectors, it serves as an essential guide for manufacturers seeking to build a resilient and scalable presence in the Indian market.Highlights & Strategic Takeaways:A Proven India Market Entry Framework: A four-pillar approach covering research, business setup, supply chain localisation, and long-term growth.Real Success Stories: What global giants like Apple, Hyundai, and IKEA won in India by adapting to local demand and operational realities.Insights for Emerging Market Entrants: UAE and Malaysia-based companies prioritise India’s growth and competitive costs, but face workforce, regulatory, and IP-related hurdles.Digital & Trade Enablers: How UPI, ONDC, and Free Trade Agreements (like CEPA and ECTA) are creating new competitive advantages for manufacturers.“India is not just a big market—it’s a complex one. For Southeast Asian companies, entering India without the right regulatory, supply chain, and cultural game plan is risky. This whitepaper is our answer to help them succeed,” said Alok Kumar, Founder & Managing DirectorThis whitepaper is an essential resource for business strategists assessing market viability or C-suite executives considering expansion to confidently and clearly navigate the India opportunity.Download the Whitepaper NowWhy Do Global Manufacturers Struggle with India Market EntryAbout SRKay Consulting GroupSRKay Consulting Group is a global consulting firm that helps companies expand into emerging markets like India through data-led strategies, market entry advisory, and operational consulting. With deep expertise in regulatory compliance, digital infrastructure, and supply chain localization, SRKay is the trusted partner for Southeast Asian firms entering India.For expert consultation and partnership opportunities, connect with:Komaldeep KaurEmail: Komal@mianext.com  Copyright 2025 ACN Newswire via SeaPRwire.com.